Merck KGaA (MKGAF) reports robust performance with 4% organic growth and confirms 2024 targets despite currency challenges.

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

FRANKFURT, Nov 14 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...